Media

Corgentech Appoints Richard B. Brewer to Board of Directors

SOUTH SAN FRANCISCO, Calif., Apr 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, announced today that Richard B. Brewer has been appointed to the Company's board of directors.

"Dick has unparalleled background and experience building companies and commercializing some of world's leading cardiovascular and other products," said John P. McLaughlin, Corgentech's president and chief executive officer. "We look forward to his guidance as we advance our lead product candidate, E2F Decoy, toward the market, and as we develop our other promising drug candidates in our pipeline, including those for inflammatory diseases and cancer."

Corgentech is developing E2F Decoy (edifoligide sodium), which is currently in the final stages of two Phase 3 clinical trials, for the prevention of bypass graft failure following coronary artery bypass graft (CABG) and peripheral (i.e., in the leg) bypass graft surgery. Both trials have been fully enrolled and have FDA Fast Track Status. The Company has an agreement with Bristol-Myers Squibb to jointly develop and commercialize E2F Decoy, and co-promote the product in the United States.

Mr. Brewer brings nearly 30 years of biopharmaceutical industry experience to Corgentech. He is the founding partner of Crest Asset Management, where he provides management counsel to healthcare and biotechnology companies and invests in select high-potential opportunities. Most recently, he spent five years as the chief executive officer and president of Scios Inc., a biopharmaceutical company focused on treatments for cardiovascular and inflammatory diseases, and cancer.

At Scios, Mr. Brewer led the company to an FDA approval for their novel protein therapeutic Natrecor(R), which has become one of the most successful and widely used cardiovascular drugs in the acute care setting. In addition, he led the growth of Scios from a small biotechnology company into one with more than 700 employees and a broad product pipeline. In 2003, Brewer guided Scios through its $2.4 billion merger with Johnson & Johnson.

Previously, Mr. Brewer was Genentech's senior vice president of sales and marketing and senior vice president of Genentech Europe and Canada. In this position, Mr. Brewer had overall management responsibilities for the establishment and development of Genentech's European operations and, in addition, spearheaded all global product launches prior to 1995. Mr. Brewer also previously served as the Chief Operating Officer at Heartport, a cardiovascular device company focused on the same target market being addressed by E2F decoy.

Mr. Brewer also serves on the boards of Dendreon, Agensys and Corus Pharma and is a past chairman of the American Heart Association's Pharmaceutical Roundtable. An active patient advocate, he is serving as an advisory board member for the Center for Accelerating Medical Solutions (CAMS) and is an advisory board member at the Kellogg Graduate School of Management Center for Biotechnology at Northwestern University. Mr. Brewer holds a B.S. degree from Virginia Polytechnic Institute, and an MBA from Northwestern University.

About Corgentech

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, such as arthritis, and cancer. For more information on the company and its technology, visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation all statements related to our clinical trials, product candidates and collaboration with Bristol-Myers Squibb. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of our clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, manufacturing our lead product candidate, competition from other pharmaceutical or biotechnology companies, our ability to obtain additional financing to support our operations and other risks detailed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE Corgentech Inc.

Richard Powers of Corgentech Inc., +1-650-624-9600, or
[email protected]; or Kristin Nash of WeissCom Partners,
+1-415-302-7951, or [email protected], for Corgentech Inc.

http://www.corgentech.com

News Provided by COMTEX